Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
Go back to Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 528.04 +30.03 (6.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $498.01 | 52 Week High | $134.71 | |||
| Open | $503.76 | 52 Week Low | $73.31 | |||
| Day High | $529.14 | P/E | N/A | |||
| Day Low | $501.53 | EPS | $-1.98 | |||
| Volume | 1,879,133 | |||||
